-
BEYOND THE HEALTH SECTOR: ESTIMATING THE SOCIETAL AND FISCAL IMPACT OF PRIMARY BILIARY CHOLANGITIS IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
UNMET MEDICAL NEED AND BURDEN OF OBESITY ON PATIENTS, PAYERS, AND HEALTH SYSTEMS IN CANADA, THE USA, AND ENGLAND
Mar 18, 2026, 21:38 PM -
WHY AI PROOF-OF-CONCEPTS DO NOT NECESSARILY PROVE ANYTHING: JOURNEY FROM POC TO PRODUCT
Mar 18, 2026, 21:38 PM -
A PORTFOLIO MODELING FRAMEWORK FOR HEOR DECISION MAKING
Mar 18, 2026, 21:38 PM -
A MIXED-METHODS STUDY TO EXPLORE THE HEALTH-RELATED QUALITY OF LIFE IMPACT ON CAREGIVERS OF CHILDREN WITH HEREDITARY ANGIOEDEMA
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS, OUTCOMES, AND RESOURCE UTILIZATION IN US ADULTS WITH NF1-PN
Mar 18, 2026, 21:38 PM -
HISTORIC PRICE DIFFERENTIALS AND MOST-FAVORED NATION PRESCRIPTION DRUG PRICING POLICY IMPACT: SCENARIO ANALYSIS USING POLI DATA ACROSS EIGHT GLOBAL MARKETS
Mar 18, 2026, 21:38 PM -
TARGET TRIAL EMULATION (TTE) INFORMED BY CLINICAL TRIAL DATA: ADJUVANT NIVOLUMAB VS OBSERVATION IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (RNSCLC) AFTER NEOADJUVANT NIVOLUMAB PLUS CHEMOTHERAPY AND SURGERY
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION IN LONG-TERM CARE RESIDENTS WITH AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE TREATED WITH BREXPIPRAZOLE
Mar 18, 2026, 21:38 PM -
ELICITING CANCER PROGRESSION RATES FOR LOCALLY/REGIONAL RECURRENT (LR) POPULATIONS USING AGGREGATE LEVEL SURVIVAL DATA: AN ILLUSTRATION FROM MELANOMA
Mar 18, 2026, 21:38 PM -
ESTIMATING HETEROGENEOUS TREATMENT EFFECTS FOR PHARMACOEPIDEMIOLOGIC STUDIES: A SCOPING REVIEW FOR CAUSAL FOREST MODELS
Mar 18, 2026, 21:38 PM -
AUTOMATING BRIEFING BOOK DEVELOPMENT FOR NICE HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS USING GENERATIVE AI
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF NEOADJUVANT AND ADJUVANT PEMBROLIZUMAB IN LOCALLY ADVANCED HEAD AND NECK CANCER
Mar 18, 2026, 21:38 PM -
CLINICAL AND ECONOMIC BENEFITS OF EARLY ROMOSOZUMAB INITIATION IN PATIENTS WITH RECENT OSTEOPOROTIC HIP FRACTURES IN JAPAN
Mar 18, 2026, 21:38 PM -
THE IMPACT OF DIFFERENT TIME-VARYING NETWORK META-ANALYSIS METHODS TO ASSESS TALAZOPARIB + ENZALUTAMIDE VERSUS OLAPARIB + ABIRATERONE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT AND COST CALCULATOR MODEL FOR POHERDY® (PERTUZUMAB-DPZB) IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER
Mar 18, 2026, 21:38 PM -
A COMPARATOR CHOICE SET FRAMEWORK FOR VALUE-BASED PRICING UNDER THE INFLATION REDUCTION ACT
Mar 18, 2026, 21:38 PM -
LEVERAGING A NATIONAL AMBULATORY CARE CLINIC NETWORK FOR REAL-WORLD EVIDENCE: INSIGHTS FROM A LARGE US EHR DATASET
Mar 18, 2026, 21:38 PM -
DIRECT MEDICAL COSTS IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): A REAL-WORLD EVIDENCE FROM FOUR CENTERS IN COLOMBIA
Mar 18, 2026, 21:38 PM -
RISK OF INFECTIOUS DISEASES AMONG OLDER US ADULTS WITH ALZHEIMER’S DISEASE COMPARED WITH THOSE WITHOUT IN NURSING HOME AND COMMUNITY SETTINGS: A CLAIMS-BASED COHORT STUDY
Mar 18, 2026, 21:38 PM
